The Long View
What the filings say about each company’s story, dilution and cash runway. Updated after each earnings report. Don't see a stock? Request it →
▲ better · ▼ worse · ⚠ watch · ● unchanged, latest quarter · share count · cash
45 companies
| Latest quarter | Funding | |||
|---|---|---|---|---|
| Corcept Therapeutics CORT | Self-funding | |||
| Xencor XNCR | company: into 2029 | |||
| Arrowhead Pharmaceuticals ARWR | company: 12+ months from Nov 2026 | |||
| Instacart (Maplebear) CART | Self-funding | |||
| Caterpillar CAT | Self-funding | |||
| CoStar Group CSGP | Self-funding | |||
| Fortinet FTNT | Self-funding | |||
| Genmab GMAB | Self-funding | |||
| Alphabet GOOGL | Self-funding | |||
| IDEXX Laboratories IDXX | Self-funding | |||
| Illumina ILMN | Self-funding | |||
| Immunocore IMCR | company: 12+ months from Nov 2026 | |||
| Innodata INOD | Self-funding | |||
| Iovance Biotherapeutics IOVA | company: into 2029 | |||
| Moderna MRNA | ||||
| Rocket Lab RKLB | ||||
| Sea Limited SE | Self-funding | |||
| Tango Therapeutics TNGX | company: into 2030 | |||
| GeneDx Holdings WGS | ||||
| Agios Pharmaceuticals AGIO | ||||
| Hims & Hers HIMS | Self-funding | |||
| TG Therapeutics TGTX | Self-funding | |||
| Vera Therapeutics VERA | ||||
| Alnylam Pharmaceuticals ALNY | Self-funding | |||
| Astera Labs ALAB | Self-funding | |||
| Gartner IT | Self-funding | |||
| Madrigal Pharmaceuticals MDGL | ||||
| Palantir Technologies PLTR | Self-funding | |||
| Krystal Biotech KRYS | Self-funding | |||
| Corning GLW | Self-funding | |||
| Reddit RDDT | Self-funding | |||
| Credit Acceptance CACC | Self-funding | |||
| Coinbase COIN | Self-funding | |||
| ServiceNow NOW | Self-funding | |||
| Viking Therapeutics VKTX | ||||
| CATL (Contemporary Amperex Technology) CYATY | Self-funding | |||
| GE Vernova GEV | Self-funding | |||
| IG Group IGGHY | Self-funding | |||
| Pentair PNR | Self-funding | |||
| Symbotic SYM | Self-funding | |||
| UniFirst UNF | Self-funding | |||
| Bloom Energy BE | Self-funding | |||
| Meta Platforms META | Self-funding | |||
| Nvidia NVDA | Self-funding | |||
| ORIC Pharmaceuticals ORIC | company: into H2 2028 |
Signals: the latest quarter, driver by driver (▲ better · ▼ worse · ⚠ watch · ● unchanged). Dilution scale, our rule of thumb: under 1% a year low, 1–3% moderate, over 3% high. Not investment advice.